Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
To the Editor: Nielsen and colleagues recently commented on our work regarding clozapine-induced acute renal failure (CIARF). These comments were extremely informative and generate further thought on the issue of clozapine rechallenge. The authors state: "It is highly important that any patient who experienced a serious/potentially life threatening ADR [adverse drug reaction] with clozapine who is later rechallenged is reflected in the literature, so that we can learn more about under which circumstances clozapine rechallenge is or is not safe."
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
Please sign in or purchase this PDF for $40.00.